|
1
|
Jemal A, Bray F, Center MM, et al: Global
cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sark W: Epidemiology of prostate cancer
and its precursors. Mod Pathol. 10:10382004.(Epub ahead of print).
View Article : Google Scholar
|
|
3
|
Tefekli A and Tunc M: Future prospects in
the diagnosis and management of localized prostate cancer. Sci
World J. 2013:3472632013. View Article : Google Scholar
|
|
4
|
Hsing A and Chokkalingam A: Prostate
cancer epidemiology. Front Biosci. 11:1388–1413. 2006. View Article : Google Scholar
|
|
5
|
Porkka K and Visakorpi T: Molecular
mechanisms of prostate cancer. Eur Urol. 45:683–691. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lee C, Jia Z, Rahmatpanah F, Zhang Q, Zi
X, McClelland M and Mercola D: Role of the adjacent stroma cells in
prostate cancer development and progression: synergy between TGF-β
and IGF signaling. Biomed Res Int. 2014:5020932014.
|
|
7
|
Bifulco M, Malfitano A, Pisanti S and
Laezza C: Endocannabinoids in endocrine and related tumours. Endocr
Relat Cancer. 15:391–408. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hermanson DJ and Marnett LJ: Cannabinoids,
endocannabinoids, and cancer. Cancer Metastasis Rev. 30:599–612.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Díaz-Laviada I: The endocannabinoid system
in prostate cancer. Nat Rev Urol. 8:553–561. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Devane WA, Dysarz FA, Johnson MR, et al:
Determination and characterization of a cannabinoid receptor in rat
brain. Mol Pharmacol. 34:605–613. 1998.
|
|
11
|
Van Dross R, Soliman E, Jha S, et al:
Receptor-dependent and receptor-independent endocannabinoid
signaling: A therapeutic target for regulation of cancer growth.
Life Sci. 92:463–466. 2013. View Article : Google Scholar
|
|
12
|
Guindon J and Hohmann AG: The
endocannabinoid system and cancer: therapeutic implication. Br J
Pharmacol. 16:1447–1463. 2011. View Article : Google Scholar
|
|
13
|
Pisanti S and Bifulco M: Endocannabinoid
system modulation in cancer biology and therapy. Pharmacol Res.
60:107–116. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kirkham TC and Tucci SA: Endocannabinoids
in appetite control and the treatment of obesity. CNS Neurol Disord
Drug Targets. 5:272–292. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bovolin P, Cottone E, Pomatto V, et al:
Endocannabinoids are involved in male vertebrate reproduction:
regulatory mechanisms at central and gonadal level. Front
Endocrinol (Lausanne). 5:542014.
|
|
16
|
Jiang W, Zhang Y, Xiao L, Van Cleemput J,
Ji SP, Bai G and Zhang X: Cannabinoids promote embryonic and adult
hippocampus neurogenesis and produce anxiolytic- and
antidepressant-like effects. J Clin Invest. 115:3104–3116. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cridge BJ and Rosengren RJ: Critical
appraisal of the potential use of cannabinoids in cancer
management. Cancer Manag Res. 30:301–313. 2013.
|
|
18
|
Batista LA, Gobira PH, Viana TG, et al:
Inhibition of endocannabinoid neuronal uptake and hydrolysis as
strategies for developing anxiolytic drugs. Behav Pharmacol.
25:425–433. 2014.PubMed/NCBI
|
|
19
|
Bifulco M, Laezza C, Pisanti S and
Gazzerro P: Cannabinoids and cancer: pros and cons of an antitumor
strategy. Br J Pharmacol. 148:123–135. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ramos JA and Bianco FJ: The role of
cannabinoids in prostate cancer: Basic science perspective and
potential clinical applications. Indian J Urol. 28:9–14. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Melck D, Rueda D, Galve-Roperh I, et al:
Involvement of the cAMP/protein kinase A pathway and of
mitogen-activated protein kinase in the anti-proliferative effects
of anandamide in human breast cancer cells. FEBS Lett. 463:235–240.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Nithipatikom K, Endsley M, Isbell M, et
al: 2-Arachidonoyl-glycerol: a novel inhibitor of
androgen-independent prostate cancer cell invasion. Cancer Res.
15:8826–8830. 2004. View Article : Google Scholar
|
|
23
|
Portella G, Laezza C, Laccetti P, et al:
Inhibitory effects of cannabinoid CB1 receptor stimulation on tumor
growth and metastatic spreading: actions on signals involved in
angiogenesis and metastasis. FASEB J. 17:1771–1773. 2003.PubMed/NCBI
|
|
24
|
Melck D, De Petrocellis L, Orlando P, et
al: Suppression of nerve growth factor Trk receptor and prolactin
receptors by endocannabinoids leads to inhibition of human breast
and prostate cancer cell proliferation. Endocrinology. 141:118–126.
2000.
|
|
25
|
Czifra G, Varga A, Nyeste K, et al:
Increased expressions of cannabinoid receptor-1 and transient
receptor potential vanilloid-1 in human prostate carcinoma. J
Cancer Res Clin Oncol. 135:507–514. 2009. View Article : Google Scholar
|
|
26
|
Mimeault M, Pommery N, Wattez N, et al:
Anti-proliferative and apoptotic effects of anandamide in human
prostatic cancer cell lines: implication of epidermal growth factor
receptor down-regulation and ceramide production. Postate. 15:1–12.
2003. View Article : Google Scholar
|
|
27
|
Ruiz L, Miguel A and Díaz-Laviada I:
Delta9-tetrahydro-cannabinol induces apoptosis in human prostate
PC-3 cells via a receptor-independent mechanism. FEBS Lett.
458:400–404. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sarfaraz S, Afaq F, Adhami VM and Mukhtar
H: Cannabinoid receptor as a novel target for the treatment of
prostate cancer. Cancer Res. 65:1635–1641. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Gómez del Pulgar T, Velasco G and Guzmán
M: The CB1 cannabinoid receptor is coupled to the activation of
protein kinase B/Akt. Biochem J. 347:369–373. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Gómez del Pulgar T, Velasco G, Sánchez C,
et al: De novo-synthesized ceramide is involved in
cannabinoid-induced apoptosis. Biochem J. 363:183–188. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Rueda D, Galve-Roperh I, Haro A and Guzmán
M: The CB1 cannabinoid receptor is coupled to the activation of
c-Jun N-terminal kinase. Mol Pharmacol. 58:814–820. 2000.PubMed/NCBI
|
|
32
|
Mendoza P, Sánchez C, Contreras HR, et al:
Evaluation of MENT on primary cell cultures from benign prostatic
hyperplasia and prostate carcinoma. Int J Androl. 32:607–615. 2009.
View Article : Google Scholar
|
|
33
|
Chunga S, Hammarstenb P, Josefssonb A, et
al: A high cannabinoid CB(1) receptor immunoreactivity is
associated with disease severity and outcome in prostate cancer.
Eur J Cancer. 45:174–182. 2009. View Article : Google Scholar
|
|
34
|
Brown L, Cascio M, Wahle K, et al:
Cannabinoid receptor- dependent and -independent anti-proliferative
effects of omega-3 ethanolamides in androgen receptor-positive
and-negative prostate cancer cell lines. Carcinogenesis.
31:1584–1591. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Nithipatikom K, Isbell M, Endsleya M, et
al: Anti-proliferative effect of a putative endocannabinoid,
2-arachidonylglyceryl ether in prostate carcinoma cells.
Prostaglandins Other Lipid Mediat. 94:34–43. 2011. View Article : Google Scholar :
|
|
36
|
Olea-Herrero N, Vara D, Malagarie-Cazenave
S and Díaz-Laviada I: Inhibition of human tumour prostate PC-3 cell
growth by cannabinoids R(+)-Methanandamide and JWH-015: involvement
of CB2. Br J Cancer. 101:940–950. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Agudelo M, Newton C, Widen R, et al:
Cannabinoid receptor 2 (CB2) mediates immunoglobulin class
switching from IgM to IgE in cultures of murine-purified B
lymphocytes. J Neuroimmune Pharmacol. 3:35–42. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kelman Z: PCNA: structure, function and
interactions. Oncogene. 6:629–640. 1997. View Article : Google Scholar
|
|
39
|
Song G, Ouyang G and Bao S: The activation
of Akt/PKB signaling pathway and cell survival. J Cell Mol Med.
1:59–71. 2005. View Article : Google Scholar
|
|
40
|
Greenhough A, Patsos H, Ann C, et al: The
cannabinoid D9-tetrahydrocannabinol inhibits RAS-MAPK and PI3K-AKT
survival signalling and induces BAD-mediated apoptosis in
colorectal cancer cells. Int J Cancer. 121:2172–2180. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
De Petrocellis L, Ligresti A, Moriello A,
et al: Non-THC cannabinoids inhibit prostate carcinoma growth in
vitro and in vivo: pro-apoptotic effects and underlying mechanisms.
Br J Pharmacol. 168:79–102. 2013. View Article : Google Scholar :
|
|
42
|
Hsu SS, Huang CJ, Cheng HH, et al:
Anandamide-induced Ca2+ elevation leading to p38 MAPK
phosphorylation and subsequent cell death via apoptosis in human
osteosarcoma cells. Toxicology. 28:21–29. 2007. View Article : Google Scholar
|
